Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
Open Access
- 1 August 2010
- journal article
- review article
- Published by Informa UK Limited in Clinical Interventions in Aging
- Vol. 5, 229-38
- https://doi.org/10.2147/cia.s6456
Abstract
Peer reviewed article authored by (Werner Poewe, Angelo Antonini, Jan CM Zijlmans, et al). Read article or submit your manuscript for publishing.Keywords
This publication has 77 references indexed in Scilit:
- Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson DiseaseArchives of Neurology, 2009
- Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's diseaseMovement Disorders, 2004
- Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET studyAnnals of Neurology, 2003
- Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)Acta Neurologica Scandinavica, 2002
- Ten-year follow-up of three different initial treatments in de-novo PDNeurology, 2001
- Levodopa prolongs life expectancy and is non-toxic to substantia nigraParkinsonism & Related Disorders, 2001
- Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's diseaseMovement Disorders, 1998
- Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.1995
- Intense oxidative DNA damage promoted by l‐DOPA and its metabolites implications for neurodegenerative diseaseFEBS Letters, 1994
- Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeysExperimental Neurology, 1992